{"version":"1.0","provider_name":"The Medical Xchange","provider_url":"https:\/\/themedicalxchange.com\/fr\/","title":"Une \u00e9tude de Phase III vient valider un nouvel agent biologique exer\u00e7ant s\u00e9lectivement son activit\u00e9 dans l\u2019intestin - The Medical Xchange","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"eXxCtoDUVi\"><a href=\"https:\/\/themedicalxchange.com\/fr\/2012\/11\/05\/reunion-scientifique-annuelle-et-cours-de-perfecti\/\">Une \u00e9tude de Phase III vient valider un nouvel agent biologique exer\u00e7ant s\u00e9lectivement son activit\u00e9 dans l\u2019intestin<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/themedicalxchange.com\/fr\/2012\/11\/05\/reunion-scientifique-annuelle-et-cours-de-perfecti\/embed\/#?secret=eXxCtoDUVi\" width=\"600\" height=\"338\" title=\"\u00ab\u00a0Une \u00e9tude de Phase III vient valider un nouvel agent biologique exer\u00e7ant s\u00e9lectivement son activit\u00e9 dans l\u2019intestin\u00a0\u00bb &#8212; The Medical Xchange\" data-secret=\"eXxCtoDUVi\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/themedicalxchange.com\/wp-includes\/js\/wp-embed.min.js\n\/* ]]> *\/\n<\/script>\n","thumbnail_url":"https:\/\/themedicalxchange.com\/wp-content\/uploads\/2012\/11\/ACG_7005_Figure_1_FR.PNG","thumbnail_width":960,"thumbnail_height":720,"description":"Las Vegas \u2013 \u00c0 la lumi\u00e8re des donn\u00e9es issues d\u2019une \u00e9tude de Phase III, un nouvel agent biologique dot\u00e9 d\u2019une activit\u00e9 s\u00e9lective unique en son genre serait sur le point d\u2019\u00eatre homologu\u00e9 pour le traitement des maladies intestinales inflammatoires (MII). Ce m\u00e9dicament, le v\u00e9dolizumab, cible l\u2019int\u00e9grine \u03b14\u03b27, qui dirige les lymphocytes T vers l\u2019intestin. L\u2019incidence des complications infectieuses enregistr\u00e9e au cours de deux essais de Phase III, l\u2019un ayant port\u00e9 sur la colite ulc\u00e9reuse (GEMINI I) et l\u2019autre, sur la maladie de Crohn (GEMINI II), \u00e9tait si faible comparativement \u00e0 celle qui est g\u00e9n\u00e9ralement observ\u00e9e avec les inhibiteurs du facteur de n\u00e9crose tumorale (TNF) qu\u2019elle porte \u00e0 croire que le mode d\u2019action particulier de cet agent pourrait pr\u00e9senter un grand int\u00e9r\u00eat sur le plan clinique pour le traitement des MII."}